Corlopam

SIDE EFFECTS

Adult Patients: Fenoldopam causes a dose-related fall in blood pressure
and increase in heart rate (see PRECAUTIONS,Tachycardia, and Hypotension). In controlled clinical studies
of severe hypertension in patients with end-organ damage, 3% (4/137) of patients
withdrew because of excessive falls in blood pressure. Increased heart rate
could, in theory, lead to ischemic cardiac events or worsened heart failure,
although these events have not been observed. The most common events reported
as associated with fenoldopam use are headache, cutaneous dilation (flushing),
nausea, and hypotension, each reported in more than 5% of patients.

Adverse reactions in controlled trials in hypertensive adult patients

Adverse events occurring more than once in any dosing group (once if potentially important or plausibly drug-related) in the fixed-dose constant-infusion studies are presented in the following Table by infusion-rate group. There was no clear dose relationship, except possibly for headache, nausea, flushing.

Pediatric Patients: In pediatric patients, the most common adverse events
reported during short term administration in controlled trials (30 minutes)
were hypotension and tachycardia. However, because of the short exposure, there
is limited experience with defining adverse events in children. The long-term
effects of fenoldopam on growth and development have not been studied.

DRUG INTERACTIONS

General: Although there have been no formal interaction studies, intravenous
fenoldopam has been administered safely with drugs such as digitalis and sublingual
nitroglycerin. There is limited experience with concomitant antihypertensive
agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and
diuretics (both thiazide-like and loop).

Last reviewed on RxList: 10/24/2008
This monograph has been modified to include the generic and brand name in many instances.